Introduction
Acute cardiac decompensation (ACD) is the most frequent cause of hospitalization in the Western world [1, 2] . Its pathophysiology is being abundantly studied with a view to lower the high rehospitalization rates and mortality associated with it. The pathologic interaction between heart and kidney, also known as cardio-renal syndrome, is one of the greatest therapeutic challenges [3, 4] . Worsening renal function (WRF), defined as a >0.3 mg/dl increase in serum creatinine concentration, occurs in approximately 25% of patients admitted to hospital for management of ACD [5, 6] . Although the mechanisms of WRF have not been completely clarified, a low cardiac output, elevation of the central blood pressure, renin-aldosterone-angiotensin axis dysfunction, sympathetic hyperactivity, oxidative injury, and a reduced renal perfusion are important contributing factors [4] . In previous studies, WRF has been associated with a high mortality and rehospitalization rate [5, 7] . However, several recent studies are conflicting with this observation and the prognostic value of inhospital WRF remains contentious [8] [9] [10] [11] [12] [13] [14] .
Although various markers have been identified as potential contributors to the cardio-renal syndrome in the past decade, nearly all studies have defined in-hospital WRF as a rise in serum creatinine or in estimated glomerular filtration rate (eGFR) calculated from it. Cystatin-C (Cys-C) is a recently described marker of renal function [16, 17] . Its serum concentration is not modified by age, gender, race, or muscle mass, and changes in eGFR could be more accurately and rapidly detected with Cys-C than with creatinine [18, 19] . Cys-C is also a better predictor of mortality and adverse cardiovascular events than serum creatinine-based estimates in acute and chronic heart failure [20] [21] [22] [23] . However, the changes in Cys-C during hospitalization for ACD and its prognostic contribution have rarely been reported and are controversial [24] [25] [26] . This observational study examined the changes in Cys-C during treatment of ACD, its associations with other factors, and its prognostic contribution in patients presenting with ACD.
Materials and methods
We studied 100 Japanese patients admitted to our hospital between February 2009 and March 2012 for management of ACD diagnosed based on the typical symptoms and signs such as dyspnea at rest or minimal effort with signs of pulmonary and/or peripheral congestion, chest radiograph, 12-lead electrocardiogram (ECG), laboratory tests, echocardiography, and according to current guidelines [27] . During hospitalization, the patients were treated with a vasodilator and a diuretic, with or without inotrope, as necessary. Patients presenting with (a) an acute myocardial infarction, (b) shock, defined as hypotension requiring continuous infusions of norepinephrine, (c) an overt infection, (d) a serum creatinine concentration >3 mg/dl, or (e) a need for hemodialysis or a mechanical cardiac assist device or mechanical ventilator were excluded from this study. We also excluded the patients who died during the initial hospitalization, who underwent a cardiac operation during the initial hospitalization or during the followup, or whose follow-up data were not available (Fig. 1 ). The present study was approved by the Ethical Committee of Hyogo Prefectural Amagasaki Hospital and conducted in compliance with the Declaration of Helsinki.
Study measurements
After verification of the patients' medical histories and drug regimens, blood samples were obtained within 6 h and 4 days after their admission to the hospital, and analyzed for serum hemoglobin, albumin, bilirubin, blood urea nitrogen (BUN), creatinine, Cys-C, electrolytes, and N-terminal pro B-type natriuretic peptide. Cys-C was measured, using the latex agglutination-turbidimetric immunoassay (IATRO Cys-C; Mitsubishi Chemical Medicine Corporation, Tokyo, Japan), with a cut-off value of 1.0 mg/l. As a categorical variable, according to the change in Cys-C, the patients were divided between a group in whom the Cys-C serum concentration (a) increased between day 1 and day 4 (Cys DAY 4 > DAY 1 ) and (b) the Cys-C serum concentration decreased or remained unchanged between day 1 and day 4 (Cys DAY 4 DAY 1 ). Similarly, they were divided between a group in whom (a) eGFR increased or remained unchanged between day 1 and day 4 (eGFR DAY 4 ! DAY 1 ) and (b) eGFR decreased between day 1 and day 4 (eGFR DAY 4 < DAY 1 ).
The primary endpoint of the study was a composite of (a) deaths from all causes and (b) unplanned re-hospitalizations for management of ACD.
Statistical analysis
The categorical variables are expressed as counts and percentages and the normally distributed continuous variables as means AE standard deviation (SD). Because body mass index and the serum concentrations of bilirubin, creatinine, Cys-C, and N-terminal pro B-type natriuretic peptide were not normally distributed, they were log-transformed for the analysis, and are expressed as medians (25th to 75th percentiles). Differences in serum Cys-C concentrations between day 1 and day 4 were examined by Wilcoxon signed-rank test. Differences in clinical and laboratory measurements between baseline and day 4 in patients with Cys DAY 4 > DAY 1 and patients with Cys DAY 4 DAY 1 were tested by Fisher's exact test for categorical variables and Student's t-test or Wilcoxon rank sum test, for continuous variables, as appropriate.
Kaplan-Meier curves were constructed to examine the effect of changes in Cys-C and eGFR on the adverse event-free survival, and the differences in survival rates were tested by log-rank test. We also examined by Cox proportional hazard regression analysis whether the association between changes in Cys-C and event-free survival influenced the outcome of ACD independently from other variables. Variables that emerged with a p-value <0.10 by single variable analysis, including systolic blood pressure, and sodium, potassium, bilirubin, inotrope use, and Cys DAY 4 > DAY 1 concentrations besides age and gender, were entered in a multiple variable regression analysis. To ascertain the effect of baseline renal function on the change in Cys-C concentration, we added the concentration of Cys-C on admission to the hospital in the analysis. All analyses were two-sided, with p < 0.05 considered statistically significant. The analyses were performed with the JMP 1 , version 10.0 software (SAS Corporation, Cary, NC, USA).
Results

Baseline patient characteristics
We enrolled 100 patients who met the inclusion criteria and whose characteristics are shown in Table 1 . Their average age was 75 years and 53% were men.
Changes in renal function during the treatment period
The median serum Cys-C concentration increased from 1.29 (0.88-1.66) mg/l on day 1, to 1.31 (1.00-1.84) mg/l on day 4 (p < 0.001; Fig. 2 ). Between day 1 and day 4, the mean BUN increased from 24 AE 11 mg/l g/dl to 25 AE 11 mg/l g/dl, and mean eGFR decreased from 50 AE 22 ml/min/1.73 m 2 to 49 AE 22 ml/min/ 1.73 m 2 , although neither change was statistically significant.
Baseline characteristics of patients whose Cys-C serum concentration increased during treatment
The Cys-C concentration increased during treatment of ACD in 66 patients, from 1.09 (0.82-1.56) mg/l on day 1 to 1.25 (0.96-1.78) mg/l on day 4. Their baseline characteristics are compared with those of the patients whose Cys-C concentration did not increase in Table 1 . Patients in the Cys DAY 4 > DAY 1 group had a higher prevalence of atrial fibrillation, a lower left ventricular ejection fraction and higher heart rate, and were less often treated with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or a loop diuretic on admission to the hospital. They also had lower creatinine, BUN, and Cys-C serum concentrations. 
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Survival analysis
Over 180 days of follow-up, 4 patients died and 26 were rehospitalized for management of ACD. The incidence of primary study endpoint was lower in the Cys DAY 4 > DAY 1 than in the Cys DAY 4 DAY 1 group (p = 0.040; Fig. 3A) , although it was similar in patients with eGFR DAY 4 < DAY 1 and patients with eGFR DAY 4 ! DAY 1 (p = 0.541, Fig. 3B ). By single variable Cox regression analysis, high systolic and diastolic blood pressures, high sodium and potassium, and low bilirubin concentrations at baseline, and (a) increase in Cys-C concentration and the absence of (b) inotrope use during treatment were associated with low rates of primary study endpoints (Table 2) . Neither the baseline nor the day 4 eGFR, BUN, and Cys-C serum concentrations were associated with death or re-hospitalization for ACD. Because there were only 30 events during the study period, we examined multiple variable regression analysis in several models of different number of covariates. High baseline sodium and an increase in Cys-C serum concentration between day 1 and day 4 were independent predictors of lower rates of death and re-hospitalization for ACD in all models nevertheless (Table 2) . Moreover, after the addition of baseline Cys-C serum concentration to the multiple variable regression analysis, Cys DAY 4 > DAY 1 remained an independent predictor of primary study endpoint (HR 0.362; 95% CI 0.146-0.816; p = 0.015). We also constructed the multivariate model without Cys-C parameters but with renal parameters such as increase in creatinine or increase in BUN or decrease in eGFR, but no renal parameter was an independent predictor of primary study endpoint.
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Discussion
In this study, fewer patients whose blood concentration of Cys-C increased during hospitalization for ACD died or were rehospitalized for management of ACD over a 180-day follow-up than patients whose Cys-C did not increase. On the other hand, the long-term rate of death and re-hospitalization for management of ACD was similar in patients whose eGFR decreased or increased during the initial hospitalization for ACD. Renal function, whether at the time of hospitalization or at the time of discharge from the hospital, was not a predictor of long-term clinical outcome. These observations are in conflict with several recent studies, which reported that in-hospital WRF is a predictor of adverse clinical outcomes. Testani et al. found that aggressive fluid removal was strongly associated with WRF and a significant decrease in 180-day survival [8] . In the DOSE trial, a strategy of high-dose furosemide administration was associated with a more abundant diuresis and transient WRF, as well as improvements in some outcome measures [9] . Other recent studies have reported the association of hemoconcentration with WRF during treatment of ACD and favorable long-term prognosis [11] [12] [13] . In the EVEREST trial, hemoconcentration was associated with a higher incidence of inhospital WRF, although renal function returned to baseline within 4 weeks after discharge of the patients from the hospital [13] . These observations support the hypothesis that WRF developing during treatment of ACD is caused by transient abnormalities in renal hemodynamics due to vigorous decongestion, vasodilation, or both. These studies also revealed a tendency for vigorous volume reduction during treatment of ACD to improve the long-term clinical outcomes. However, Metra et al. found that WRF in patients with signs of persistent congestion was explained by other pathophysiologic mechanisms than volume reduction alone and that, in these circumstances, WRF might be associated with adverse long-term clinical outcomes [14] . In this study, an increase in Cys-C, although not a decrease in eGFR, was associated with a lower long-term, event-free survival. This may reflect the properties of Cys-C, which can detect changes in GFR more reliably and rapidly than creatinine. So, recently a Japanese chronic kidney disease guideline recommended us to estimate GFR by Cys-C in addition to creatinine [15] . This might also mean that patients in the Cys DAY 4 > DAY 1 had undergone effective decongestion, and were generally responsive to treatment, which is concordant with their tendency to be less medicated with loop diuretics and to present with a preserved renal function at the time of hospitalization. Patients entering the hospital without a regimen of angiotensin-converting inhibitor or angiotensin receptor blocker can also develop in-hospital WRF, although respond favorably to the introduction of these medications during treatment of ACD.
The prognosis of patients who develop WRF or acute kidney injury during treatment of ACD varies depending on the threshold that has been adopted, as they can be divided between a group that responds to treatment of ACD and in whom the abnormalities of renal function are transient, versus a group refractory to treatment of ACD, in whom the hemodynamic impairment and fluid overload are major. In the latter group, the low cardiac output and high central and renal venous pressures may lower the glomerular filtration pressure and cause WRF. This may explain the higher incidence of atrial fibrillation, lower mean left ventricular ejection fraction, and higher heart rate at the time of hospitalization in patients presenting with Cys DAY 4 > DAY 1 , whose cardiac output may be depressed and renal function worsened.
In patients with chronic or acute heart failure, a depressed renal function has generally been associated with a poor prognosis [28] [29] [30] , an observation confirmed in studies using Cys-C [21, 22] . In this study, the indices of renal function measured at the time of admission and discharge from the hospital did not predict the long-term prognosis, as observed in a few previous studies [10] . We believe that this is partly explained by changes from baseline, caused by ACD, in the indices of renal function. In some patients, renal function preserved during the chronic phase is depressed by transient congestion or low perfusion, while others, whose renal function is chronically impaired, recover a relatively better function by transient hemodilution during the hospitalization. Therefore, the measurements made at the time of hospitalization do not always reflect the true renal function [31] . We believe, therefore that, besides the baseline measurements, the changes in renal function observed during treatment of ACD might more accurately reflect the patient's long-term prognosis. N-terminal pro B-type natriuretic peptide at the time of admission is also known to be a strong predictor of adverse outcome in ACD patients. In this study, high N-terminal pro B-type natriuretic peptide value at the time of admission tended to be associated with higher rate of primary endpoints but not significantly as in other small studies.
Limitations of the study
The association between increase in Cys-C and decreased rate of long-term adverse clinical events indicates a correlation between marker of WRF and favorable prognosis after ACD. This should promote the search for new markers in the urine or blood to detect true irreversible renal injury and correlate its occurrence with adverse prognosis. On the other hand, since Cys-C exerts various biological functions, it is possible that its changes reflect other pathologic processes, separate from eGFR, that influence the longterm prognosis [32, 33] . Our study was also limited by the lack of direct measurements of GFR. If we would have systematically followed the renal function after discharge, in-hospital WRF may have been considered as a transient change with confirmation.
Conclusion
An increase in Cys-C serum concentration during hospitalization for management of ACD was associated with a decreased risk of death or re-hospitalization for ACD independently of the baseline renal function. This observation is consistent with recent studies, which found that in-hospital WRF based on measurements of creatinine was not associated with an adverse long-term prognosis. 
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